Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR3 S249C |
| Therapy | Anlotinib + Irinotecan |
| Indication/Tumor Type | adult spinal cord glioblastoma multiforme |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 S249C | adult spinal cord glioblastoma multiforme | predicted - sensitive | Anlotinib + Irinotecan | Case Reports/Case Series | Actionable | In a clinical case study, Anlotinib (AL-3818) and Camptosar (irinotecan) combination treatment resulted in symptom improvement and a partial response maintained for at least 10 months in a patient with IDH wild-type primary spinal cord glioblastoma harboring FGFR3 S249C (PMID: 35847381). | 35847381 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35847381) | Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma with FGFR3 Mutation. | Full reference... |